Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 70HER2-positive Breast Cancer 15HER2 Positive Metastatic Breast Cancer 4Breast Diseases 4HER2 Positive Breast Cancer 3Brain Neoplasms 3Advanced Breast Cancer 3Triple Negative Breast Neoplasms 2HER2-positive Metastatic Breast Cancer 2Breast Cancer Invasive 2Breast Cancer Female 2Stomach Neoplasms 1Pathologic Complete Response 1Neoplasm Metastasis 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Metastatic Breast Cancer in the Brain 1Locally Advanced Breast Cancer 1HER2-positive Early Breast Cancer 1HER2-positive Advanced Breast Cancer 1HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1HER2+ Early or Locally Advanced Breast Cancer 1HER2+ Breast Cancer 1Estrogen Receptor-positive Breast Cancer 1Breast Neoplasm Female 1Breast Cancer Metastatic 1

Interventions

Trastuzumab 5Carboplatin 5Docetaxel 4pertuzumab 3Paclitaxel 3Cyclophosphamide 3pembrolizumab 2Epirubicin 2Doxorubicin 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1taxane 1talazoparib 1sarilumab 1pyrotinib 1pirarubicin 1pexidartinib 1patritumab 1olaparib 1niraparib 1neratinib 1ganitumab 1durvalumab 1dostarlimab 1cemiplimab 1abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × pyrotinib × Breast × Clear all
NCT05659056 2024-04-16

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
65 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡